Patient Perspectives - Patient Reported Outcomes Drive Drug Development, but Improving Patient Involvement Remains a Challenge



Summary



GBI Research, the leading business intelligence provider, has released its latest research, “Patient Perspectives - Patient Reported Outcomes Drive Drug Development, but Improving Patient Involvement Remains a Challenge”. The report examines the role of patients in changing the research agenda and helping pharma companies to bring effective medicines that meet real unmet medical needs into the market place. It explores the use of patient reported outcomes in drug development, with a particular focus on their use in the regulatory setting. The report investigates whether the measures used in clinical development are relevant to patients and describes current initiatives to improve patient involvement. The final chapter explores the way in which patient involvement is changing as a result of online interactions.

The report is built using information from primary and secondary research including interview with experts in the field.

GBI Research analysis shows that regulators and reimbursement authorities are driving efforts to involve patients in drug development through initiating projects to find out what matters most to patients and including this in their own benefit-risk or value assessments. Pharmaceutical companies will need to take this changing environment into consideration more carefully when designing strategies across the board, as well as in defining the particulars of individual development programs and clinical trials. Company strategies should depend on identifying key areas of unmet need as patients in these areas may be willing to take more risks and reimbursement authorities will be more willing to finance new, and potentially expensive, treatments for drugs in these areas.



Scope


- History of patient involvement in drug development, regulation and reimbursement.
- Definitions and regulatory status of Patient-Reported Outcome measures and electronic Patient-Reported Outcome measures.
- Detailed analysis of Patient-Reported Outcome instrument development and collaborations underway to accelerate their development in key therapeutic areas.
- Analysis of patient relevance in the assessment of a new drug’s value by health technology assessors and reimbursement authorities.
- Growth of online communities of patients with particular diseases and their relevance in drug development.



Reasons to buy


- Identify the best ways to work with patients to improve drug development.
- Identify key projects that are developing methods for involving patients more closely in decision making and agenda setting activities.
- Develop strategies for Patient-Reported Outcome instrument development.
- Understand the current thinking amongst regulators and reimbursement authorities with regards to Patient-Reported Outcome measures.
- Explore ways in which to interact with patients online or to use information generated by online communities to support new research strategies.

Table Of Contents

Table of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
3 Patient Perspectives - Regulatory Focus 9
3.1 The US FDA 9
3.2 European Medicines Agency 10
3.3 Patient Perspectives - Reimbursement Focus 11
3.4 Patients and the Pharmaceutical Industry 12
3.4.1 The EU Patient Partnership Project 12
3.4.2 The Drug Information Association (DIA) Patient Fellowship Program 14
3.4.3 The James Lind Alliance 14
3.4.4 Engaging the Pharmaceutical Industry 15
3.5 Overcoming Barriers to Patient Involvement 16
4 Patient Reported Outcomes 17
4.1 Introduction 17
4.2 Regulatory Guidance 18
4.2.1 FDA Guidance 18
4.2.2 EMA Reflection Paper 18
4.2.3 Influence of EMA and FDA Guidance Documents 19
4.3 Using PROs in drug development 20
4.3.1 PRO Instrument Development and the FDA 21
4.3.2 Contract Research Organisations with PRO Expertise 21
4.3.3 PRO Instruments: Sharing and Cooperation 22
4.3.4 Electronic PRO instruments 24
4.4 Conclusions 25
5 Ensuring Patient Relevance in Value Assessments 26
5.1 Introduction 26
5.2 Patient Preference Data in Quantifying Benefit-Risk Decisions 26
5.3 Patient-preference Data in Reimbursement Decision-making 28
5.3.1 Quality Adjusted Life Years and HRQL Data 28
5.3.2 Patient involvement with NICE 30
5.3.3 Patient Preference Methods 31
5.3.4 Conjoint analysis 32
5.3.5 Qualitative Studies of Patient Preference 33
5.4 Patient Perspectives and Comparative Effectiveness Research in the US 33
5.4.1 The US Patient Centered Outcomes Research Institute (PCORI) 33
5.5 Conclusions 35
6 Patients Online 36
6.1 Introduction 36
6.2 Tracking, Monitoring and Sharing Data 36
6.2.1 Quantified Self 37
6.2.2 wikiLife 37
6.3 E-communities 38
6.3.1 PatientsLikeMe.com 38
6.3.2 CureTogether.com 39
6.4 Patients, Social Media and Personalized Medicine 39
6.5 Conclusions 40
6.6 Future Outlook 40
7 Appendix 41
7.1 Key Definitions 41
7.2 Abbreviations (in alphabetical order) 41
7.3 References (in alphabetical order) 42
7.4 Methodology 44
7.4.1 Primary Research 45
7.4.2 Secondary Research 45
7.5 Contacts Us 45
7.6 Disclaimer 46

List of Tables

1.1 List of Tables
Table 1: Patient Perspectives, Role of Patient-reported Outcomes and Health-related Quality of Life Data in Product Labelling in the US and EU, 2006-2010 19
Table 2: Patient Perspectives, Examples of Contract Research Organizations with Expertise in Patient-Reported Outcomes 21
Table 3: Patient Perspectives, Potential Benefits of ePRO Solutions 24

List of Figures

1.2 List of Figures
Figure 1: Patient Perspectives, Patients’ and Consumers’ Organizations Working with the EMA 11
Figure 2: Patient Perspectives, Potential Barriers Towards Patient Involvement: Results of the Patient Partner Project Survey 13
Figure 3: Patient Perspectives, Schizophrenia Research Priorities Identified through the James Lind Alliance 15
Figure 4: Patient Perspectives, Examples of Disease Areas and Relevant Primary Endpoints 17
Figure 5: Patient Perspectives, Process for Including Patient Reported Outcome Measures in Drug Development 20
Figure 6: Patient Perspectives, Pharmaceutical Companies Working Together for Patient-Reported Outcome Instrument Development in the Critical Path Institute’s PRO Consortium 22
Figure 7: Patient Perspectives, The Process Used By The Critical Path Institute’s PRO Consortium for PRO Instrument Development 23
Figure 8: Patient Perspectives, History of Regulatory Actions on Quantitative Benefit-Risk Analysis 26
Figure 9: Patient Perspectives, Schematic of the BRAT Framework,2011 27
Figure 10: Patient Perspectives, Steps in the BRAT Framework, 2011 27
Figure 11: Patient Perspectives, Quality Adjusted Life Years in Practice, 2009 28
Figure 12: Patient Perspectives, Difference in Focus for HRQL and Patient Pereference Methods for Determining Value, 2007 31
Figure 13: Patient Perspectives, PatientsLikeMe.com 38

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Enabling Technological Platforms for Lab-on-Chip Applications  (Technical Insights)

Enabling Technological Platforms for Lab-on-Chip Applications (Technical Insights)

  • $ 6 500
  • Industry report
  • June 2014
  • by Frost & Sullivan

6 Dimensional Assessment of Lab on a Chip Innovation Landscape A growing trend towards miniaturizing laboratory practices has been a major driving force behind the steady increase of innovations in the ...

Biologicals in Oncology Drug Pipeline Update 2014

Biologicals in Oncology Drug Pipeline Update 2014

  • $ 3 749
  • Industry report
  • July 2014
  • by Bioseeker

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 908 companies plus partners developing 1686 biological ...

Biologicals in Oncology: Drug Pathway Analyzer 2014

Biologicals in Oncology: Drug Pathway Analyzer 2014

  • $ 3 675
  • Industry report
  • July 2014
  • by Bioseeker

Extra value: One year of free online updates included with this product There are today at least 1421 biological drugs known to affect more than 266 specific intracellular signaling pathways for the treatment ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.